SBRT of Lung and Liver Tumors
Stereotactic Body Radiation Therapy (SBRT) — also known as SABR (Stereotactic Ablative Radiotherapy) — is an advanced, high-precision radiation technique that delivers very high doses of radiation to a tumor in a few focused sessions, with sub-millimetre accuracy.
Unlike conventional radiation, which is given over several weeks, SBRT typically completes treatment in 1 to 5 sessions, targeting the tumor while sparing surrounding normal tissue.
SBRT has emerged as a curative alternative to surgery for selected lung and liver tumors, particularly in patients who are not surgical candidates due to age, comorbidities, or tumor location.
-
SBRT combines:
-
High-precision imaging (CT, MRI, PET-CT) to visualize the tumor in real time.
-
Immobilization devices to minimize movement.
-
Advanced planning systems that shape the radiation dose around the tumor.
-
Image-Guided Radiation Therapy (IGRT) and 4D-CT respiratory motion management to account for breathing and organ movement.
-
These enable clinicians to deliver a potent, curative dose of radiation safely and accurately.
-
1. Early-Stage (Primary) Lung Cancer
SBRT is now considered standard of care for medically inoperable patients with Stage I non-small cell lung cancer (NSCLC).
Benefits:
-
Local control rates >90% (comparable to surgery)
-
Non-invasive, outpatient procedure
-
No anesthesia or incisions required
-
Minimal recovery time
Indications:
-
Small, well-defined peripheral lung tumors
-
Patients unfit for lobectomy due to poor pulmonary reserve or cardiac issues
-
Residual or recurrent disease after surgery
Techniques Used:
-
4D-CT simulation to capture breathing motion
-
Respiratory gating or tracking to synchronize beam delivery with tumor movement
-
IMRT / VMAT for highly conformal dose distribution
-
-
The liver is a radiosensitive organ that moves with respiration, making precision critical.
SBRT, with its sub-millimetre targeting and motion management, allows safe and effective treatment of both primary liver cancers (Hepatocellular Carcinoma) and liver metastases. -
Indications:
-
Inoperable or unresectable HCC
-
Liver metastases from colorectal, breast, or other primaries
-
Recurrence after surgery or ablation
-
Bridging therapy before liver transplantation
-
Benefits:
-
Non-invasive alternative to radiofrequency ablation (RFA) or surgery
-
High local control rates (80–95%)
-
Preserves surrounding healthy liver tissue
-
Can be repeated if necessary
-
Techniques Used:
-
4D-CT simulation and fiducial markers for tracking tumor motion
-
Abdominal compression or breath-hold gating to reduce movement
-
IGRT / Cone-beam CT for daily verification
-
-
Curative potential for small, localized lung or liver tumors
-
Organ preservation — no surgery, no blood loss
-
Short, outpatient treatment schedule
-
Minimal pain and recovery time
-
Excellent local control and survival rates
-
Option for re-irradiation or recurrence management
-
-
SBRT is generally well tolerated. Side effects, when present, are usually mild and transient:
-
Lung SBRT:
-
Fatigue
-
Mild cough or shortness of breath
-
Rare radiation pneumonitis
-
Liver SBRT:
-
Mild nausea or abdominal discomfort
-
Temporary elevation of liver enzymes
-
Rare radiation-induced liver disease (RILD)
-
Careful patient selection and advanced planning significantly minimize risks.
-
-
SBRT for lung and liver tumors represents a major advancement in modern radiation oncology — offering surgical precision without surgery.
-
It provides a curative, non-invasive alternative for early-stage or limited metastatic disease, combining cutting-edge technology with exceptional patient comfort.
-
Through the synergy of precision imaging, motion management, and targeted radiation delivery, SBRT continues to redefine cancer care — achieving cure, control, and quality of life for patients once considered untreatable by conventional methods.
-
